Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of 11,000,000shares of its common stock at…
Chemed Corporation (NYSE: CHE) – After more than three decades, Executive Vice President and Chief Financial Officer David P. Williams has announced that he will retire as Chemed’s Chief Financial Officer as of December 31, 2023, but Mr. Williams will continue to work with Chemed for…
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 40-cents per share on the Company’s capital stock, payable on December 4, 2023, to shareholders of record as of November 13, 2023. This is equal to the dividend…
Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced DocDefender, a free service for physicians that tracks down and eliminates their personal contact information from public websites. In an environment of escalating violence and harassment against…
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating the fifth annual BOTOX® Cosmetic Day on Wednesday, November 15. To commemorate this milestone, the brand is expanding its offerings like never before. New and loyal members of Allē, the Allergan Aesthetics loyalty program, have…
Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2023. “Baxter continues to successfully execute upon the slate of strategic actions we announced at the outset of 2023,” said José (Joe) E. Almeida,…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the treatment of patients…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, met its key secondary endpoint of overall survival (OS), for the adjuvant treatment of…
Pfizer Inc. (NYSE: PFE) will present its latest data showcasing advances in the treatment of hemophilia, sickle cell disease, and blood cancers at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from December 9-12. These data…
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new discovery data from an ongoing study exploring the potential for developing a complementary, minimally invasive test to evaluate small, suspicious lesions…
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its third quarter 2023 financial results before the stock market opens on Monday, November 13,…
Modivcare Inc. (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today reported financial results for the three and nine months ended September 30,…